The week’s biggest numbers did not buy a single new device. BD committed $19 billion to US factories in exchange for tariff relief that does not exist yet, GE HealthCare paid $945 million for other people’s cyclotrons, and a London startup raised $50 million on the premise that the queue to get certified is itself a market. The most consequential safety notice of the week, meanwhile, concerned a handheld ultrasound that wants a Wi-Fi signal before it will let you scan.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🏛️ BD trades $19B in US factories for tariff relief that is not written yet
BD will invest $19 billion in the US over several years, $3 billion of it in manufacturing expansion across eight sites, to lift domestic supply of essential consumables to roughly 80% and make every US needle domestically from American steel. In return it gets relief from future Section 232 device tariffs, contingent on final scope, implementation, and milestones BD has to hit. The company is not quantifying the benefit, which tells you how firm the other side of this trade is.
BD
2.🧾 AdvaMed wants CMS’s new coverage fast lane widened
Comments on RAPID, the CMS pathway that would hand FDA-designated breakthrough devices a proposed national coverage determination, close October 13. AdvaMed called it a positive step and then asked for most of it to change: broader breakthrough eligibility, diagnostics included, firm NCD timelines, transition protection for devices already queued under older pathways. CMS thinks about 40 devices qualify today, against nearly 1,300 breakthrough designations granted. That ratio is the whole argument.
MedTech Dive
3. 🚨 Four deaths tied to a handheld ultrasound that needs a signal to scan
FDA issued an early alert on Philips Lumify after two software faults: the app can stop recognizing a registered transducer and demand re-registration, which needs Wi-Fi or cellular, and the USB transducer connection can drop mid-scan. Philips has reported eight serious injuries and four deaths, and told customers in a September 24 letter to keep a backup scanner within reach. A point-of-care device whose failure mode is connectivity is a hard thing to sell into an ambulance.
FDA
🧰 A full commercial team for your next milestone. No hiring required.
A raise, a launch, or a first hospital contract needs messaging that holds up, investor and sales materials, a website, and regulatory and manufacturing partners who all know where you’re headed. RŌG Health gives you that team now. We start with where you’re headed and what’s in the way. Then we bring our own people and a bench of partner firms in regulatory, manufacturing, and commercial execution, all working from the same plan and telling the same story. When the work is done, it adds up to one company instead of six deliverables.
Book 30 minutes with the RŌG Health team →
Sponsored by RŌG Health
4. ☢️ GE HealthCare buys the last mile of PET
GE HealthCare will pay $945 million in cash to Trilantic North America for Sofie Biosciences: 15 contract manufacturing sites running 21 cyclotrons, a theranostics CDMO, and US rights to FAPI-74, a Phase 3 PET tracer. Sofie keeps operating independently and keeps supplying rivals’ products. With a 110-minute half-life on F18 tracers, distribution geography is the moat in radiopharma, and GE bought it rather than built it. Close is expected by July 2027.
Radiology Business
5. 💼 Stryker replaces the CEO who tripled it
Kevin Lobo hands the chief executive job to president and COO Spencer Stiles on January 1, 2027, and becomes executive chair. Lobo ran Stryker for 14 years, taking net sales from $8.7 billion in 2012 to more than $26 billion this year across 60-plus acquisitions, Mako included. Stiles joined the Endoscopy business in 1999 and later led the Wright Medical deal and the spine separation. An internal, pre-announced, five-quarter handoff is the opposite of a surprise.
Stryker
6. ⚖️ Apple owes Masimo another $184M, and the clock started in 2020
A California federal court added $184.2 million in prejudgment interest to Masimo’s $634 million pulse oximetry verdict, bringing the total to $818.5 million. The court ran interest from January 2020, when it found Apple should have struck a royalty deal, and used Masimo’s own cost of borrowing, a figure taken from one of Apple’s trial experts. Dating the royalty clock to 2020 instead of the verdict is what turned one nine-figure loss into most of another.
MassDevice
7. 🤖 Robotic microsurgery raises $125M
MMI closed a $125 million Series D led by BioStar Capital, with S3 Ventures, Angelini Ventures, and an undisclosed strategic investor. The Symani system, FDA-authorized and CE marked, pairs wristed microinstruments with tremor reduction and motion scaling; roughly 50 systems are installed and 3,500 procedures done. The money goes to adoption, energy instruments, and the REMIND study. Fifty placements in a decade says microsurgery robotics is a procedure-creation problem, not a selling problem.
MD+DI
8. ✅ A $50M bet that the certification queue is the market
Scarlet, a London certification body designated under EU MDR and recognized by the MHRA and as an FDA third-party reviewer, raised a $50 million Series B led by Headline, with Notion Capital joining Atomico, Creandum, and Kindred. It is one of roughly 52 EU notified bodies and says it is the only one built for software and AI, selling subscription surveillance instead of one-off audits. When a minor update takes six to eight months to clear, the reviewer becomes a vendor choice.
Tech.eu
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.